San Diego's DermTech trims staff to conserve cash as it pushes scalpel-free diagnostic test for melanoma
Biotech firm also suspends research on certain programs to focus resources on its non-invasive, genomics based-test for skin cancer
Stay updated with breaking news from John Dobak. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Biotech firm also suspends research on certain programs to focus resources on its non-invasive, genomics based-test for skin cancer
DermTech, Inc. , a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced the appointment of Bret Christensen, previously chief commercial officer of... | May 9, 2023
DermTech (Nasdaq:DMTK) announced today that it appointed Bret Christensen as president, CEO and a member of the board.
Operator: Good day and thank you for standing by. Welcome to DermTech’s First Quarter 2023 Financial Results Call. At this time, all participants are in a listen-only mode.
DermTech (NASDAQ:DMTK – Get Rating) is scheduled to be releasing its earnings data after the market closes on Thursday, May 4th. Analysts expect DermTech to post earnings of ($0.90) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link. DermTech (NASDAQ:DMTK – Get […]